Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 661 to 670 of 769

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Botulinum toxin type A for the prevention of headaches in adults with chronic migraineTA260
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254
Pharmalgen for the treatment of bee and wasp venom allergyTA246
Tocilizumab for the treatment of rheumatoid arthritisTA247
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Rituximab for the first-line treatment of stage III-IV follicular lymphomaTA243
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adultsTA245
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238

Results per page

  1. 10
  2. 25
  3. 50
  4. All